Ubs Asset Management Americas Inc Lexicon Pharmaceuticals, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 120,387 shares of LXRX stock, worth $85,474. This represents 0.0% of its overall portfolio holdings.

Number of Shares

120,387

Holding current value

$85,474

% of portfolio

0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.51 - $2.39 $181,784 - $287,724	120,387 New	120,387 $189,000
Q1 2023 May 15, 2023	BUY	$1.99 - $2.68 $37,191 - $50,086	18,689 Added 15.7%	137,735 $334,000
Q3 2022 Nov 14, 2022	SELL	$1.94 - $3.43 $110,393 - $195,180	-56,904 Reduced 32.34%	119,046 $285,000
Q2 2022 Aug 12, 2022	BUY	$1.31 - $2.69 $120,619 - $247,684	92,076 Added 109.78%	175,950 $327,000
Q3 2021 Nov 15, 2021	BUY	$3.38 - $5.35 $25,346 - $40,119	7,499 Added 9.82%	83,874 $403,000
Q2 2021 Aug 16, 2021	BUY	$4.12 - $5.87 $314,665 - $448,321	76,375 New	76,375 $350,000
Q2 2020 Aug 14, 2020	SELL	$1.75 - $2.3 $84,596 - $111,184	-48,341 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.8 - $4.28 $1.91 Million - $4.55 Million	-1,063,307 Reduced 95.65%	48,341 $94,000
Q4 2019 Feb 14, 2020	SELL	$3.16 - $5.15 $23,864 - $38,892	-7,552 Reduced 0.67%	1,111,648 $4.61 Million
Q3 2019 Nov 14, 2019	BUY	$1.2 - $6.66 $5,602 - $31,095	4,669 Added 0.42%	1,119,200 $3.37 Million
Q1 2019 May 14, 2019	SELL	$4.36 - $7.94 $7.97 Million - $14.5 Million	-1,827,892 Reduced 62.12%	1,114,531 $0
Q4 2018 Feb 13, 2019	SELL	$6.15 - $10.51 $5.3 Million - $9.06 Million	-861,605 Reduced 22.65%	2,942,423 $19.5 Million
Q3 2018 Nov 14, 2018	SELL	$10.32 - $13.06 $1.76 Million - $2.23 Million	-170,868 Reduced 4.3%	3,804,028 $0
Q2 2018 Aug 14, 2018	SELL	$7.8 - $13.69 $299,340 - $525,381	-38,377 Reduced 0.96%	3,974,896 $0
Q1 2018 May 14, 2018	SELL	$7.86 - $11.39 $1.16 Million - $1.68 Million	-147,199 Reduced 3.54%	4,013,273 $0
Q4 2017 Feb 09, 2018	BUY	$8.77 - $12.28 $5.11 Million - $7.16 Million	582,922 Added 16.29%	4,160,472 $0
Q3 2017 Nov 13, 2017	BUY	$12.17 - $16.3 $43.5 Million - $58.3 Million	3,577,550	3,577,550 $0

Others Institutions Holding LXRX

# of Institutions

141

Shares Held

238M

Call Options Held

459K

Put Options Held

133K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $134M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Lexicon Pharmaceuticals, Inc. Transaction History